Pub Date : 2025-09-09DOI: 10.1016/j.jbspin.2025.105959
Renaud Felten , Philippe Goupille , Daniel Wendling , Thao Pham
{"title":"Navigating clinical research challenges in spondyloarthritis: Insights from the French Spondyloarthritis Taskforce (FAST)","authors":"Renaud Felten , Philippe Goupille , Daniel Wendling , Thao Pham","doi":"10.1016/j.jbspin.2025.105959","DOIUrl":"10.1016/j.jbspin.2025.105959","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105959"},"PeriodicalIF":4.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-06DOI: 10.1016/j.jbspin.2025.105965
Lene Terslev , Hilde Berner Hammer
{"title":"Monitoring gout with ultrasound: Is it useful in daily practice?","authors":"Lene Terslev , Hilde Berner Hammer","doi":"10.1016/j.jbspin.2025.105965","DOIUrl":"10.1016/j.jbspin.2025.105965","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 2","pages":"Article 105965"},"PeriodicalIF":4.3,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To evaluate the effects of concomitant methotrexate (MTX) and predictors of remission in rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors.
Methods
This retrospective study included 681 treatment courses in 569 patients treated with JAK inhibitors. The impact of baseline variables on achieving Clinical Disease Activity Index (CDAI) remission at 24 weeks was assessed using multivariate logistic regression analysis. Disease activity was compared between groups with and without concomitant MTX use [MTX (±)] after inverse probability of treatment weighting adjustment.
Results
The estimated mean CDAI score was 17.6 at baseline and significantly decreased after 4 weeks. Proportions of patients who achieved CDAI remission were 5% at baseline, 22% at 4 weeks, 31% at 12 weeks, and 36% at 24 weeks. Multivariate analysis revealed that radiographic damage (OR: 0.48, 95% CI: 0.30–0.77), prior biological/targeted synthetic disease-modifying antirheumatic drug use (OR: 0.57, 95% CI: 0.36–0.90), glucocorticoid use (OR: 0.65, 95% CI: 0.43–0.98), and baseline CDAI score (OR: 0.96 per 1 point, 95% CI: 0.94–0.98) independently predicted CDAI remission at 24 weeks. Compared to the MTX (−) group, the MTX (+) group exhibited a significantly higher proportion of patients achieving CDAI remission at 12 weeks, whereas no significant difference was observed at 24 weeks. Subgroup analyses revealed that this difference was evident among patients with moderate to high disease activity.
Conclusion
Concomitant MTX provided potential advantages in terms of early disease control in JAK inhibitor therapy for RA, particularly in patients with active disease.
{"title":"Effects of concomitant methotrexate and predictors of remission in Janus kinase inhibitor therapy for rheumatoid arthritis","authors":"Shuji Asai , Kenya Terabe , Junya Hasegawa , Yutaka Yoshioka , Takefumi Kato , Toshihisa Kojima , Yusuke Ohno , Tomonori Kobayakawa , Tatsuo Watanabe , Yasumori Sobue , Tsuyoshi Nishiume , Mihoko Kato , Takayoshi Fujibayashi , Yuji Hirano , Yasuhide Kanayama , Toki Takemoto , Tsuyoshi Watanabe , Masahiro Hanabayashi , Hiroyuki Matsubara , Mochihito Suzuki , Shiro Imagama","doi":"10.1016/j.jbspin.2025.105961","DOIUrl":"10.1016/j.jbspin.2025.105961","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effects of concomitant methotrexate (MTX) and predictors of remission in rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors.</div></div><div><h3>Methods</h3><div>This retrospective study included 681 treatment courses in 569 patients treated with JAK inhibitors. The impact of baseline variables on achieving Clinical Disease Activity Index (CDAI) remission at 24<!--> <!-->weeks was assessed using multivariate logistic regression analysis. Disease activity was compared between groups with and without concomitant MTX use [MTX (±)] after inverse probability of treatment weighting adjustment.</div></div><div><h3>Results</h3><div>The estimated mean CDAI score was 17.6 at baseline and significantly decreased after 4<!--> <!-->weeks. Proportions of patients who achieved CDAI remission were 5% at baseline, 22% at 4<!--> <!-->weeks, 31% at 12<!--> <!-->weeks, and 36% at 24<!--> <!-->weeks. Multivariate analysis revealed that radiographic damage (OR: 0.48, 95% CI: 0.30–0.77), prior biological/targeted synthetic disease-modifying antirheumatic drug use (OR: 0.57, 95% CI: 0.36–0.90), glucocorticoid use (OR: 0.65, 95% CI: 0.43–0.98), and baseline CDAI score (OR: 0.96 per 1 point, 95% CI: 0.94–0.98) independently predicted CDAI remission at 24<!--> <!-->weeks. Compared to the MTX (−) group, the MTX (+) group exhibited a significantly higher proportion of patients achieving CDAI remission at 12<!--> <!-->weeks, whereas no significant difference was observed at 24<!--> <!-->weeks. Subgroup analyses revealed that this difference was evident among patients with moderate to high disease activity.</div></div><div><h3>Conclusion</h3><div>Concomitant MTX provided potential advantages in terms of early disease control in JAK inhibitor therapy for RA, particularly in patients with active disease.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105961"},"PeriodicalIF":4.3,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-06DOI: 10.1016/j.jbspin.2025.105964
Chi-Hung Liu , Li-Chung Chiu , Tien-Ming Chan
{"title":"Clinical significance of anti-RP11 and anti-Ro52 antibodies in patients evaluated for systemic sclerosis: Associations with interstitial lung disease and pulmonary arterial hypertension","authors":"Chi-Hung Liu , Li-Chung Chiu , Tien-Ming Chan","doi":"10.1016/j.jbspin.2025.105964","DOIUrl":"10.1016/j.jbspin.2025.105964","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105964"},"PeriodicalIF":4.3,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-02DOI: 10.1016/j.jbspin.2025.105958
Kasper Yde Jensen , Christian Sümeghy Søndergaard , Tanja Thomsen , Kirsten Schroll Bjørnsbo , Allan Linneberg , Carlijn Anne Wagenaar , Bente Appel Esbensen , Charlotte Werdal Hansen
Background
This systematic review and meta-analysis aim to assess the effects of vegan and vegetarian diets on disease activity, pain, fatigue, and physical function in people with rheumatoid arthritis.
Methods
We conducted searches on the MEDLINE, EMBASE, CINAHL, and Central electronic databases up to December 2024. Randomized controlled trials that investigated vegan or vegetarian dietary interventions (including lacto-ovo-vegetarian, vegan, or whole-food plant-based diets) in people with rheumatoid arthritis were included, and independent of outcomes measured.
Results
Of 1408 screened hits, seven trials published between 1979 and 2023 were included. Pooled analyses revealed that compared to controls, participants following vegetarian or vegan diet achieved no significant improvement in disease activity, a small significant improvement in pain, and no significant improvement in physical function. Fatigue was only assessed in one of the included studies and thus not eligible for meta-analysis. The sensitivity and subgroup analyses did not change the outcome of the meta-analysis. The overall certainty of evidence (Grading of Recommendations, Assessment, Development, and Evaluations) for the effect of vegan and vegetarian diets in patients with rheumatoid arthritis was rated as low across all outcomes.
Conclusion
The meta-analysis suggests potential beneficial effects on pain. However, due to the methodological limitations and the small number of studies included, definitive conclusions cannot yet be drawn. Future research is needed to further explore the effects of vegetarian and vegan diets.
Trial registration
The protocol was registered in PROSPERO CRD42023495226.
{"title":"Effects of vegetarian and vegan diets on disease activity, pain, fatigue, and physical function in patients with rheumatoid arthritis: A systematic review and meta-analysis","authors":"Kasper Yde Jensen , Christian Sümeghy Søndergaard , Tanja Thomsen , Kirsten Schroll Bjørnsbo , Allan Linneberg , Carlijn Anne Wagenaar , Bente Appel Esbensen , Charlotte Werdal Hansen","doi":"10.1016/j.jbspin.2025.105958","DOIUrl":"10.1016/j.jbspin.2025.105958","url":null,"abstract":"<div><h3>Background</h3><div>This systematic review and meta-analysis aim to assess the effects of vegan and vegetarian diets on disease activity, pain, fatigue, and physical function in people with rheumatoid arthritis.</div></div><div><h3>Methods</h3><div>We conducted searches on the MEDLINE, EMBASE, CINAHL, and Central electronic databases up to December 2024. Randomized controlled trials that investigated vegan or vegetarian dietary interventions (including lacto-ovo-vegetarian, vegan, or whole-food plant-based diets) in people with rheumatoid arthritis were included, and independent of outcomes measured.</div></div><div><h3>Results</h3><div>Of 1408 screened hits, seven trials published between 1979 and 2023 were included. Pooled analyses revealed that compared to controls, participants following vegetarian or vegan diet achieved no significant improvement in disease activity, a small significant improvement in pain, and no significant improvement in physical function. Fatigue was only assessed in one of the included studies and thus not eligible for meta-analysis. The sensitivity and subgroup analyses did not change the outcome of the meta-analysis. The overall certainty of evidence (Grading of Recommendations, Assessment, Development, and Evaluations) for the effect of vegan and vegetarian diets in patients with rheumatoid arthritis was rated as low across all outcomes.</div></div><div><h3>Conclusion</h3><div>The meta-analysis suggests potential beneficial effects on pain. However, due to the methodological limitations and the small number of studies included, definitive conclusions cannot yet be drawn. Future research is needed to further explore the effects of vegetarian and vegan diets.</div></div><div><h3>Trial registration</h3><div>The protocol was registered in PROSPERO CRD42023495226.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105958"},"PeriodicalIF":4.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-02DOI: 10.1016/j.jbspin.2025.105957
Bruno Fautrel , Lisa Bialé , Marion Couderc , André Basch , Frédérique Gandjbakhch , Francis Guillemin
Objective
To describe whether rheumatoid arthritis (RA) flares detected by the self-administered Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire can predict joint structural damage progression at 2 years and to explore the association between the FLARE-RA score and RA outcome measures.
Methods
Adults with RA for less than 10 years and Health Assessment Questionnaire-Disability Index (HAQ-DI) score < 1 were included in this prospective observational study. Patients were followed clinically every 6 months and completed the FLARE-RA questionnaire every 3 months at home, for 24 months. Wrist and foot X-rays were taken at inclusion and month 24 (M24). Logistic regressions and generalized linear mixed-effects models were used.
Results
The median (IQR) age of the 221 analyzed patients was 58.0 years (48.0–66.0), 67.4% were female, and the median time from RA diagnosis was 1.4 years (0.5–2.8). Most patients (84.6%) received ongoing treatment for RA, and 46.0% were in remission according to the Disease Activity Score in 28 joints (DAS28) at inclusion. Flare assessment between visits to the rheumatologist, as assessed with the FLARE-RA global score, was not associated with structural changes (OR: 1.00, 95% CI 0.99–1.01) or progression of erosions (OR = 1.00, 95% CI 0.99–1.01) at month 24 but was significantly associated with DAS28, Physician Global Assessment, HAQ-DI, Patient Acceptable Symptom State, Minimal Clinically Important Difference, and intensification of treatment for RA during follow-up (all P < 0.0001).
Conclusions
The FLARE-RA score was associated with physician-based disease activity measures, suggesting its value as a patient-reported disease-activity measure in routine care, including remote consultation.
目的：描述自用类风湿关节炎耀斑评估（Flare -RA）问卷检测类风湿关节炎（RA）耀斑是否可以预测2年关节结构损伤进展，并探讨耀斑-RA评分与RA结局指标之间的关系。结果：221例分析患者的中位（IQR）年龄为58.0岁（48.0 ~ 66.0岁），女性占67.4%，RA诊断的中位时间为1.4年（0.5 ~ 2.8年）。大多数患者（84.6%）接受了RA的持续治疗，根据纳入时28个关节的疾病活动评分（DAS28）， 46.0%的患者处于缓解期。用Flare -RA总体评分评估的风湿病学家就诊期间的发作评估与第24个月的结构改变（OR=1.00, 95% CI 0.99-1.01）或糜烂进展（OR=1.00, 95% CI 0.99-1.01）无关，但与DAS28、医生总体评估、HAQ-DI、患者可接受症状状态、最小临床重要差异和随访期间RA治疗的强化显著相关（均为p）。FLARE-RA评分与基于医生的疾病活动度测量相关，表明其作为常规护理（包括远程会诊）中患者报告的疾病活动度测量的价值。
{"title":"Association between rheumatoid arthritis flares and joint structural changes at 24 months: using FLARE-RA questionnaire","authors":"Bruno Fautrel , Lisa Bialé , Marion Couderc , André Basch , Frédérique Gandjbakhch , Francis Guillemin","doi":"10.1016/j.jbspin.2025.105957","DOIUrl":"10.1016/j.jbspin.2025.105957","url":null,"abstract":"<div><h3>Objective</h3><div>To describe whether rheumatoid arthritis (RA) flares detected by the self-administered Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire can predict joint structural damage progression at 2 years and to explore the association between the FLARE-RA score and RA outcome measures.</div></div><div><h3>Methods</h3><div>Adults with RA for less than 10 years and Health Assessment Questionnaire-Disability Index (HAQ-DI) score<!--> <!--><<!--> <!-->1 were included in this prospective observational study. Patients were followed clinically every 6 months and completed the FLARE-RA questionnaire every 3 months at home, for 24 months. Wrist and foot X-rays were taken at inclusion and month 24 (M24). Logistic regressions and generalized linear mixed-effects models were used.</div></div><div><h3>Results</h3><div>The median (IQR) age of the 221 analyzed patients was 58.0 years (48.0–66.0), 67.4% were female, and the median time from RA diagnosis was 1.4 years (0.5–2.8). Most patients (84.6%) received ongoing treatment for RA, and 46.0% were in remission according to the Disease Activity Score in 28 joints (DAS28) at inclusion. Flare assessment between visits to the rheumatologist, as assessed with the FLARE-RA global score, was not associated with structural changes (OR: 1.00, 95% CI 0.99–1.01) or progression of erosions (OR<!--> <!-->=<!--> <!-->1.00, 95% CI 0.99–1.01) at month 24 but was significantly associated with DAS28, Physician Global Assessment, HAQ-DI, Patient Acceptable Symptom State, Minimal Clinically Important Difference, and intensification of treatment for RA during follow-up (all <em>P</em> <!--><<!--> <!-->0.0001).</div></div><div><h3>Conclusions</h3><div>The FLARE-RA score was associated with physician-based disease activity measures, suggesting its value as a patient-reported disease-activity measure in routine care, including remote consultation.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105957"},"PeriodicalIF":4.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-02DOI: 10.1016/j.jbspin.2025.105956
Anne-Christine Rat , Jean-Hugues Salmon , Willy Ngueyon Sime , Alain Saraux , Claudine Gard , Francis Guillemin , Bruno Fautrel
Objective
To describe the health care use of patients with symptomatic knee or hip OA and to identify factors associated with health care use trajectories over a 10-year period.
Methods
This study used longitudinal data from the multicentre “Knee-and-Hip-OsteoArthritis-Long-term-Assessment” cohort, which comprised 878 patients with OA diagnoses confirmed by both a physician and radiographic evidence. We identified homogeneous subgroups of trajectories based on individual health care consumption over time via latent class growth analysis. Logistic regression analysis determined baseline factors associated with these trajectories.
Results
A minority of patients consulted a specialist. Impaired mental health was associated with moderate- and high-probability trajectories of consulting a primary care physician (PCP), a physical therapist and a rheumatologist (ORs 0.7 [0.6–0.9] to 0.9 [0.8–0.96]). High pain levels were associated only with high probability of consulting an orthopaedic surgeon (OS) (OR 0.8 [0.7–0.9]). Rheumatologist consultations were more likely in large cities (OR 2.3 [1.3–4.1]), and OS consultations were associated with a high level of education (OR 3.6 [1.3–7.4]).
Conclusions
PCPs play a central role in OA care. High pain levels were associated mainly with a high probability of consulting an OS, whereas mental health status was a major predictive factor of other health care professional consultations. Mental health state is probably insufficiently accounted for. Social inequalities persist and must be considered in public health policies.
{"title":"Health care practices in symptomatic knee and hip osteoarthritis patients: The KHOALA cohort","authors":"Anne-Christine Rat , Jean-Hugues Salmon , Willy Ngueyon Sime , Alain Saraux , Claudine Gard , Francis Guillemin , Bruno Fautrel","doi":"10.1016/j.jbspin.2025.105956","DOIUrl":"10.1016/j.jbspin.2025.105956","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the health care use of patients with symptomatic knee or hip OA and to identify factors associated with health care use trajectories over a 10-year period.</div></div><div><h3>Methods</h3><div>This study used longitudinal data from the multicentre “Knee-and-Hip-OsteoArthritis-Long-term-Assessment” cohort, which comprised 878 patients with OA diagnoses confirmed by both a physician and radiographic evidence. We identified homogeneous subgroups of trajectories based on individual health care consumption over time via latent class growth analysis. Logistic regression analysis determined baseline factors associated with these trajectories.</div></div><div><h3>Results</h3><div>A minority of patients consulted a specialist. Impaired mental health was associated with moderate- and high-probability trajectories of consulting a primary care physician (PCP), a physical therapist and a rheumatologist (ORs 0.7 [0.6–0.9] to 0.9 [0.8–0.96]). High pain levels were associated only with high probability of consulting an orthopaedic surgeon (OS) (OR 0.8 [0.7–0.9]). Rheumatologist consultations were more likely in large cities (OR 2.3 [1.3–4.1]), and OS consultations were associated with a high level of education (OR 3.6 [1.3–7.4]).</div></div><div><h3>Conclusions</h3><div>PCPs play a central role in OA care. High pain levels were associated mainly with a high probability of consulting an OS, whereas mental health status was a major predictive factor of other health care professional consultations. Mental health state is probably insufficiently accounted for. Social inequalities persist and must be considered in public health policies.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 1","pages":"Article 105956"},"PeriodicalIF":4.3,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-28DOI: 10.1016/j.jbspin.2025.105954
Yannick Degboé , Guillaume Couture
Discontinuation of denosumab in postmenopausal osteoporosis causes a rebound phenomenon with a rapid increase in bone turnover markers and accelerated bone loss, often within 6–12 months. Without an appropriate relay therapy, up-to 10% of the patients experience multiple vertebral fractures. This phenomenon is linked to a multifactorial dysregulation of bone remodelling. In 2021, the European Calcified Tissue Society (ECTS) proposed guidelines for discontinuing denosumab in patients with postmenopausal osteoporosis. Our review covers the latest research on risk stratification for rebound phenomenon, the various relay treatment options based on risk levels, and the recommended follow-up for these patients. Post-denosumab treatment is important. Bisphosphonates therapy and regular monitoring of serum CTX (crosslaps) represent the cornerstone of the management of rebound phenomenon following denosumab discontinuation in postmenopausal osteoporosis.
{"title":"Strategies for denosumab discontinuation in postmenopausal osteoporosis","authors":"Yannick Degboé , Guillaume Couture","doi":"10.1016/j.jbspin.2025.105954","DOIUrl":"10.1016/j.jbspin.2025.105954","url":null,"abstract":"<div><div>Discontinuation of denosumab in postmenopausal osteoporosis causes a rebound phenomenon with a rapid increase in bone turnover markers and accelerated bone loss, often within 6–12 months. Without an appropriate relay therapy, up-to 10% of the patients experience multiple vertebral fractures. This phenomenon is linked to a multifactorial dysregulation of bone remodelling. In 2021, the European Calcified Tissue Society (ECTS) proposed guidelines for discontinuing denosumab in patients with postmenopausal osteoporosis. Our review covers the latest research on risk stratification for rebound phenomenon, the various relay treatment options based on risk levels, and the recommended follow-up for these patients. Post-denosumab treatment is important. Bisphosphonates therapy and regular monitoring of serum CTX (crosslaps) represent the cornerstone of the management of rebound phenomenon following denosumab discontinuation in postmenopausal osteoporosis.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"93 2","pages":"Article 105954"},"PeriodicalIF":4.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144979563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-28DOI: 10.1016/j.jbspin.2025.105955
Saskia P.M. Truijen , Annelies Boonen , Carla J.H. van der Kallen , Annemarie Koster , Hans Bosma , Marloes van Onna
Objective
To test the hypothesis that older age negatively impacts the association between chronic musculoskeletal pain (MSP) and health-related quality of life (HRQoL).
Methods
Cross-sectional data of 8618 participants aged 40–75 years from the population-based Maastricht Study cohort was used. Chronic MSP presence was self-reported. Pain intensity was measured on a 0–10 scale (10: unbearable pain). Age (seven groups) and chronic MSP (intensity) were regressed in multivariable analyses on (components of) HRQoL: the mental (MCS) and physical component score (PCS) of the 36-item Short Form Survey (SF-36), the EuroQol-VAS measuring overall HRQoL, and (un)paid work days lost in the past six months. Interactions between age groups and chronic MSP were examined.
Results
Chronic MSP was reported by 2513/8618 (29%) participants and was associated with worse PCS (β = −7.4, 95%CI: −7.8 to −7.1), MCS (β = −1.8, 95%CI: −2.2 to −1.5), EuroQol-VAS (β = −7.9, 95%CI: −8.9 to −7.0), and a higher likelihood of unproductive days (OR = 2.1, 95%CI:1.9–2.4). An interaction between age group and MSP was only observed for mental health: The negative impact of MSP on mental health was lower in individuals aged 70–75 years (β = −0.4, 95%CI: −1.3 to 0.6) compared to those aged 40–44 years (β = −3.1, 95%CI: −5.0 to −1.2) (pinteraction < 0.05). Age > 60 years was associated with fewer unproductive days, independent of MSP (ORrange age groups: 0.6 to 0.3; all P < 0.01).
Conclusion
Although chronic MSP negatively affects physical and mental health as well as work productivity, our findings suggest an unexpected resilience in mental HRQoL among older adults.
{"title":"The impact of older age on the relation between chronic musculoskeletal pain and health-related quality of life: The Maastricht Study","authors":"Saskia P.M. Truijen , Annelies Boonen , Carla J.H. van der Kallen , Annemarie Koster , Hans Bosma , Marloes van Onna","doi":"10.1016/j.jbspin.2025.105955","DOIUrl":"10.1016/j.jbspin.2025.105955","url":null,"abstract":"<div><h3>Objective</h3><div>To test the hypothesis that older age negatively impacts the association between chronic musculoskeletal pain (MSP) and health-related quality of life (HRQoL).</div></div><div><h3>Methods</h3><div>Cross-sectional data of 8618 participants aged 40–75 years from the population-based Maastricht Study cohort was used. Chronic MSP presence was self-reported. Pain intensity was measured on a 0–10 scale (10: unbearable pain). Age (seven groups) and chronic MSP (intensity) were regressed in multivariable analyses on (components of) HRQoL: the mental (MCS) and physical component score (PCS) of the 36-item Short Form Survey (SF-36), the EuroQol-VAS measuring overall HRQoL, and (un)paid work days lost in the past six months. Interactions between age groups and chronic MSP were examined.</div></div><div><h3>Results</h3><div>Chronic MSP was reported by 2513/8618 (29%) participants and was associated with worse PCS (β<!--> <!-->=<!--> <!-->−7.4, 95%CI: −7.8 to −7.1), MCS (β<!--> <!-->=<!--> <!-->−1.8, 95%CI: −2.2 to −1.5), EuroQol-VAS (β<!--> <!-->=<!--> <!-->−7.9, 95%CI: −8.9 to −7.0), and a higher likelihood of unproductive days (OR<!--> <!-->=<!--> <!-->2.1, 95%CI:1.9–2.4). An interaction between age group and MSP was only observed for mental health: The negative impact of MSP on mental health was lower in individuals aged 70–75 years (β<!--> <!-->=<!--> <!-->−0.4, 95%CI: −1.3 to 0.6) compared to those aged 40–44 years (β<!--> <!-->=<!--> <!-->−3.1, 95%CI: −5.0 to −1.2) (<em>p</em><sub>interaction</sub> <!--><<!--> <!-->0.05). Age<!--> <!-->><!--> <!-->60 years was associated with fewer unproductive days, independent of MSP (OR<sub>range</sub> age groups: 0.6 to 0.3; all <em>P</em> <!--><<!--> <!-->0.01).</div></div><div><h3>Conclusion</h3><div>Although chronic MSP negatively affects physical and mental health as well as work productivity, our findings suggest an unexpected resilience in mental HRQoL among older adults.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 6","pages":"Article 105955"},"PeriodicalIF":4.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144978897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号